Cover Image
市場調查報告書

急性骨髓性白血病 (AML) :動態市場預測

Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026

出版商 GlobalData 商品編碼 611766
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
急性骨髓性白血病 (AML) :動態市場預測 Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026
出版日期: 2017年12月22日 內容資訊: 英文 72 Pages
簡介

本報告提供急性骨髓性白血病 (AML) 治療藥市場相關調查分析,最新的預測 (法規,上市,臨床實驗活動等) 相關的系統性資訊。

第1章 動態市場預測概要

  • 相關調查
  • 未來的相關調查

第2章 摘要整理

第3章 學會:ASH 2017

第4章 活動1

  • 主要的更新
  • Jazz:Vyxeos (CPX-351)
  • 醫生的見解
  • 摘要/趨勢
  • 資訊來源

第5章 活動2

  • 主要的更新
  • 競爭情形
  • Novartis:Rydapt (midostaurin)
  • 醫生的見解
  • Arog:crenolanib
  • Astellas:gilteritinib
  • 醫生的見解
  • 摘要/趨勢
  • 資訊來源

第6章 活動3

  • 主要的更新
  • Agios/Celgene:Idhifa
  • Agios:ivosidenib
  • 醫生的見解
  • 摘要/趨勢
  • 資訊來源

第7章 活動4

  • 主要的更新
  • Pfizer:Mylotarg (gemtuzumab ozogamicin)
  • 醫生的見解
  • 附加的臨床實驗更新
  • 摘要/趨勢
  • 資訊來源

第8章 追加活動

  • 武田藥品工業:pevonedistat
  • 醫生的見解

第9章 其他活動

  • 各種開發人員
  • 資訊來源

第10章 活動日曆

第11章 附錄

目錄
Product Code: GDHC002FS

Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Conference coverage
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018

Reasons to buy

  • Recent Regulatory Events
  • Recent Commercial Events
  • Recent Clinical Events
  • New SOC expected for elderly t-AML and AML-MRC patients
  • Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
  • Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
  • US Approval of the First CD33 Targeting Agent, Mylotarg

Table of Contents

  • 1. Dynamic Market Forecast Overview 6
  • 1.1 Related Reports 7
  • 1.2 Upcoming Related Reports 8
  • 2. Executive Summary 9
  • 2.1 Key Updates to AML Market Dynamics 10
  • 2.2 Key Events in Update 11-12
  • 2.3 Updates to Treatment Algorithms 13-14
  • 2.4 Updates to Pipeline Competitive Assessment 15-16
  • 2.4 Market Insight on Key Events 17
  • 3. Conference Coverage - ASH 2017
  • 3.1 Selected Abstracts ASH2017 - AML 19-20
  • 4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
  • 4.1 Key Updates to the Frontline Setting - Elderly Patients 22
  • 4.2 Jazz, Vyxeos (CPX-351) 23-24
  • 4.3 What Do Physicians Think? 25
  • 4.4 Summary/Trends 26
  • 4.5 Sources 27
  • 5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
  • 5.1 Key Updates About the Use of FLT3 Inhibitors in the First- Line Setting 29
  • 5.2 Competitive Landscape of FLT3 Inhibitors in AML 30
  • 5.3 Novartis, Rydapt (midostaurin) 31
  • 5.4 What Do Physicians Think? 32
  • 5.5 Arog, crenolanib 33
  • 5.6 Astellas, gilteritinib 34
  • 5.7 What Do Physicians Think? 35
  • 5.8 Summary/Trends 36
  • 5.9 Sources 37
  • 6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
  • 6.1 Key Updates in IDH+ AML 39
  • 6.2 Agios/Celgene, Idhifa 40-41
  • 6.3 Agios, ivosidenib 42-44
  • 6.4 What Do Physicians Think? 45
  • 6.5 Summary/Trends 46
  • 6.6 Sources 47
  • 7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
  • 7.1 Key Updates on Mylotarg 49
  • 7.2 Pfizer, Mylotarg (gemtuzumab ozogamicin) 50
  • 7.3 What Do Physicians Think? 51
  • 7.4 Additional Clinical Trial Updates- CD33+ 52
  • 7.5 Summary/Trends 53
  • 7.6 Sources 54
  • 8. Additional Events
  • 8.1 Takeda, pevonedistat 56
  • 8.2 What Do Physicians Think? 57
  • 9. Other Events of Interest
  • 9.1 Various Developers 59
  • 9.2 Sources 60
  • 10. Events Calendar
  • 10.1 Key Events Expected to Occur in 2018 62
  • 11. Appendix
  • 11.1 Methodology 64
  • 11.2 Primary Research 65-66
  • 11.3 About the Authors 67-69
  • 11.4 About GlobalData 70
  • 11.5 Contact Us 71
  • 11.6 Disclaimer 72
Back to Top